Novel pharmacological targets for the treatment of Parkinson’s disease.

Anthony H. V. Schapira, Erwan Bezard, Jonathan Brotchie, Frédéric Calon, Graham L. Collingridge, Borris Ferger, Bastian Hengerer, Etienne Hirsch, Peter Jenner, Nicolas Le Novère, José A. Obeso, Michael A. Schwarzschild, Umberto Spampinato, Giora Davidai
Nat Rev Drug Discov. 2006-10-01; 5(10): 845-854
DOI: 10.1038/nrd2087

Lire sur PubMed

1. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.

Novel pharmacological targets for the treatment of Parkinson’s disease.

Schapira AH(1), Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B,
Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA,
Spampinato U, Davidai G.

Author information:
(1)University Department of Clinical Neurosciences, Royal Free and University
College Medical School, University College London, Rowland Hill Street, London
NW3 2PF, UK.

Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic
neurons, is the cause of the major clinical motor symptoms of Parkinson’s
disease. These symptoms can be treated successfully with a range of drugs that
include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine
agonists delivered by oral, subcutaneous, transcutaneous, intravenous or
intra-duodenal routes. However, Parkinson’s disease involves degeneration of
non-dopaminergic neurons and the treatment of the resulting predominantly
non-motor features remains a challenge. This review describes the important
recent advances that underlie the development of novel dopaminergic and
non-dopaminergic drugs for Parkinson’s disease, and also for the motor
complications that arise from the use of existing therapies.

DOI: 10.1038/nrd2087
PMID: 17016425 [Indexed for MEDLINE]

Auteurs Bordeaux Neurocampus